Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1725502 | 0.97 | ODC1 (0.30) | ODC1 | |
| Hydrochloric Acid SCHEMBL18420902 | 0.97 | KDM4E (0.32) | ODC1 | |
| Bromide SCHEMBL789378 | 0.97 | DNM1 (0.31) | ODC1 | |
| SCHEMBL6931791 | 0.90 | DNM1 (0.38) | FDPSNFKB1 | |
| SCHEMBL6933261 | 0.90 | DNM1 (0.38) | FDPSNFKB1 | |
| Bromide SCHEMBL28376789 | 0.88 | DNM1 (0.39) | FDPSNFKB1 | |
| SCHEMBL4135812 | 0.83 | — | — | |
| SCHEMBL2873269 | 0.83 | ODC1 (0.33) | ODC1FDPSPDE3ANFKB1 | |
| Bromide SCHEMBL2180760 | 0.81 | — | — | |
| SCHEMBL23395809 | 0.80 | NFKB1 (0.40) | FDPSPDE3ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404604-B1 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS INC (US) | 2019-02-06 | — | — | EP | claimed |
| US-20130309301-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2013-11-21 | — | — | US | claimed |
| EP-2404604-A1 | Salts of potassium ATP channel openers and uses thereof | Essentialis, Inc. (US) | 2012-01-11 | — | — | EP | claimed |
| EP-1968601-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100028429-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2010-02-04 | — | — | US | claimed |
| US-7572789-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2009-08-11 | — | — | US | claimed |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2009-06-11 | — | — | US | claimed |
| EP-1968601-A4 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1968601-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | Essentialis, Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2007-08-16 | — | — | US | claimed |
| WO-2007081521-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| EP-0042226-B1 | ZEOLITE EU-1 | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-08 | — | — | EP | claimed |
| EP-0042226-A1 | Zeolite EU-1 | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-12-23 | — | — | EP | claimed |
| JP-1261220-A | — | — | None | — | — | JP | disclosed |
| US-12589098-B2 | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener | SEDOGEN LLC (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240285580-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | QLARIS BIO, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| JP-H01261220-A | SYNTHESIS OF CRYSTALLINE SILICOALUMINOPHOSPHATE | MOBIL OIL CORP | 1989-10-18 | — | — | JP | disclosed |
| EP-0042226-B1 | ZEOLITE EU-1 | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-08 | — | — | EP | disclosed |
| EP-0051318-A1 | A catalyst composition containing as catalytically active components alumina and a cristalline Aluminosilicate zeolite, a process for isomerizing xylenes and ethylbenzene, and use of this catalyst composition | Teijin Petrochemical Industries Ltd. (JP) | 1982-05-12 | — | — | EP | disclosed |
| EP-0042226-A1 | Zeolite EU-1 | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028429-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | ODC1 2743/4885FDPS 1426/4885PDE3A 1539/4885 |
| US-20130309301-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | ODC1 2743/4885FDPS 1426/4885PDE3A 1539/4885 |
| US-12589098-B2 | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener | KCNJ2, KCNJ1, ATP1A2 | ODC1 1832/4885FDPS 2626/4885PDE3A 1366/4885 |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | ODC1 2743/4885FDPS 1426/4885PDE3A 1539/4885 |
| US-20240285580-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | KIT, CSNK1A1L, CSNK1G3 | ODC1 4723/4885FDPS 4271/4885PDE3A 94/4885 |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | ODC1 2743/4885FDPS 1426/4885PDE3A 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.